Expert Opinion on Emerging Drugs

Papers
(The median citation count of Expert Opinion on Emerging Drugs is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Emerging drugs for hemophilia A: insights into phase II and III clinical trials67
Emerging therapeutics in Huntington’s disease24
A review of phase II and III drugs for the treatment and management of endometriosis21
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?17
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder17
Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia15
New drugs targeting calcitonin gene-related peptide for the management of migraines14
Emerging drugs for the treatment of acne: a review of phase 2 & 3 trials13
Emerging drugs for the treatment of postsurgical pain13
Evolving role of VIADISC for chronic low back and discogenic pain: a narrative review12
How can we prevent diarrhea induced by systemic treatments in oncological patients? An evaluation of phase II trials11
Emerging medicines to improve the basic defect in cystic fibrosis11
Emerging biological treatments for asthma10
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia10
Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?9
Emerging injectable therapies for osteoarthritis9
Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials9
Cannabinoid treatment for the symptoms of autism spectrum disorder8
Emerging drugs for the treatment of herpetic keratitis8
ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?7
Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials7
Expert opinion on emerging drugs for lung chronic graft-versus-host disease7
Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria7
A review of emerging factor XI inhibitors7
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials6
Recent advances in immune-based approaches for the treatment of esophagogastric cancer6
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder6
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion6
Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma5
Emerging tyrosine kinase inhibitors for head and neck cancer5
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials5
Emerging antiviral therapies and drugs for the treatment of influenza5
Correction5
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma5
How will tovorafenib change our treatment of pediatric low-grade glioma?5
Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis4
Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results4
Emerging therapies for dry eye disease4
Review of phase 2/3 trials in polymyalgia rheumatica and giant cell arteritis4
Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials4
Monoclonal antibodies in phase II and III trials for moderate to severe atopic dermatitis4
Resiquimod: a new topical immune-response modifier for the treatment of actinic keratosis4
Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials4
Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials4
Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma4
Emerging drugs for the treatment of irritability associated with autism spectrum disorder4
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?3
Emerging drugs for the treatment of inflammatory bowel disease3
Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa3
Emerging drugs for the treatment of diabetic nephropathy3
Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma3
Correction3
Current and emerging drug treatment strategies to tackle sickle cell anemia3
Emerging drugs for the treatment of hereditary angioedema due to C1-inhibitor deficiency3
Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma3
Evaluating emerging drugs in phase II & III for the treatment of amyotrophic lateral sclerosis3
An update on emerging drugs for the treatment of hypercholesterolemia3
Emerging drugs in the treatment of chronic cough3
Systemic therapy for Child-Pugh B patients with hepatocellular carcinoma3
Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia3
What’s new on the horizon for polycystic ovarian syndrome? Exploring emerging drugs in phase II3
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity3
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond2
Emerging drugs for the treatment of major depressive disorder2
Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials2
Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder2
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials2
Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update2
Cancer drugs with high repositioning potential for Alzheimer’s disease2
An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer’s disease: the role of apolipoprotein E2
Emerging drugs for the treatment of alopecia areata2
Letter to the editor: ‘Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa’2
0.045324087142944